News & Updates

Show Multimedia Only
Add-on pyrotinib in neoadjuvant setting safe, effective for HER2-positive advanced breast cancer

Add-on pyrotinib in neoadjuvant setting safe, effective for HER2-positive advanced breast cancer

12 Sep 2022

In the treatment of patients with HER2-positive locally advanced breast cancer, adding pyrotinib to trastuzumab plus chemotherapy in the neoadjuvant setting yields high response rates while being safe, according to the results of NeoATP trial.

Add-on pyrotinib in neoadjuvant setting safe, effective for HER2-positive advanced breast cancer

12 Sep 2022
Tuberculosis survivors at risk of stroke

Tuberculosis survivors at risk of stroke

11 Sep 2022

Patients who have been treated for tuberculosis appear to have an elevated risk of ischaemic stroke compared with their counterparts who have never had the infection, according to a study.

Tuberculosis survivors at risk of stroke

11 Sep 2022
STRIDE regimen benefit in unresectable HCC consistent across baseline liver function

STRIDE regimen benefit in unresectable HCC consistent across baseline liver function

11 Sep 2022